Global PoC molecular diagnostics market will reach $5,665.3 million by 2030, growing by 13.5% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 87 tables and 86 figures, this 183-page report Global Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porters Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Region.
Based on Product, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Kits & Assays
- Analyzers & Instruments
- Software & Services
Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Polymerase Chain Reaction (PCR)
- Real-Time PCR (rt-PCR)
- Digital PCR (d-PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Genetic Sequencing-based Technology
Microarray-based Technology
Other Technologies
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Infectious Disease
- Respiratory Infections
- Hospital Acquired Infections
- Sexually Transmitted Infections
Gastrointestinal Infections
Oncology
Hepatitis
Prenatal/Neonatal Testing
Other Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Hospitals
- Clinics & Diagnostic Centers
- Research and Academic Institutes
- Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
- North America (U.S., Canada, and Mexico)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global PoC molecular diagnostics market are assayed quantitatively and qualitatively through GMDs Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abacus Diagnostica Oy
Abbott Laboratories
Alere Inc.
Biocartis Group NV
Biomerieux SA
Bio-Rad Laboratories Inc
Danaher Corporation
DiaSorin S.p.A
DxNA LLC.
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Luminex Corporation
Meridian Bioscience Inc.
Mesa Biotech Inc.
QIAGEN N.V.
QuantuMDx Group Ltd.
Quidel Corporation
Spartan Biosciences Inc.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)